These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31147215)

  • 1. Positive pharmacokinetic effect of azathioprine co-medication on infliximab trough levels is dose-dependent.
    Polakovicova V; Kadleckova B; Lucenicova J; Otottova K; Kinova S; Mikus P; Zelinkova Z
    Dig Liver Dis; 2019 Aug; 51(8):1112-1116. PubMed ID: 31147215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment.
    Larsen L; Jess T; Drewes AM; Dige A; Fallingborg J; Jacobsen BA; Aagaard B; Agnholt J
    Eur J Gastroenterol Hepatol; 2019 Aug; 31(8):964-967. PubMed ID: 31094854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of azathioprine dose in combined treatment with anti-TNF-alpha in inflammatory bowel disease.
    Lucas Ramos J; Suárez Ferrer C; Poza Cordón J; Sánchez Azofra M; Rueda García JL; Martin Arranz E; Yebra Carmona J; Andaluz García I; Martín Arranz MD
    Gastroenterol Hepatol; 2021 May; 44(5):337-345. PubMed ID: 33272733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial.
    Roblin X; Boschetti G; Williet N; Nancey S; Marotte H; Berger A; Phelip JM; Peyrin-Biroulet L; Colombel JF; Del Tedesco E; Paul S; Flourie B
    Aliment Pharmacol Ther; 2017 Jul; 46(2):142-149. PubMed ID: 28449228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice.
    Buurman DJ; Maurer JM; Keizer RJ; Kosterink JG; Dijkstra G
    Aliment Pharmacol Ther; 2015 Sep; 42(5):529-39. PubMed ID: 26113313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
    Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
    Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
    Orfanoudaki E; Gazouli M; Foteinogiannopoulou K; Theodoraki E; Legaki E; Romanos I; Mouzas I; Koutroubakis IE
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases.
    Williet N; Paul S; Peyrin-Biroulet L; Roblin X
    Dig Dis Sci; 2016 Apr; 61(4):990-5. PubMed ID: 26669880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design.
    Santacana E; Rodríguez-Alonso L; Padullés A; Guardiola J; Bas J; Rodríguez-Moranta F; Serra K; Morandeira F; Colom H; Padullés N
    Ther Drug Monit; 2020 Feb; 42(1):102-110. PubMed ID: 31283556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD.
    van Schaik T; Maljaars JP; Roopram RK; Verwey MH; Ipenburg N; Hardwick JC; Veenendaal RA; van der Meulen-de Jong AE
    Inflamm Bowel Dis; 2014 Dec; 20(12):2292-8. PubMed ID: 25230167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.
    Roblin X; Williet N; Boschetti G; Phelip JM; Del Tedesco E; Berger AE; Vedrines P; Duru G; Peyrin-Biroulet L; Nancey S; Flourie B; Paul S
    Gut; 2020 Jul; 69(7):1206-1212. PubMed ID: 31980448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease.
    Pallagi-Kunstár É; Farkas K; Szepes Z; Nagy F; Szűcs M; Kui R; Gyulai R; Bálint A; Wittmann T; Molnár T
    World J Gastroenterol; 2014 May; 20(17):5031-5. PubMed ID: 24833846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD.
    Nasser Y; Labetoulle R; Harzallah I; Berger AE; Roblin X; Paul S
    Dig Dis Sci; 2018 Oct; 63(10):2714-2721. PubMed ID: 29948562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients.
    Dubinsky MC; Phan BL; Singh N; Rabizadeh S; Mould DR
    AAPS J; 2017 Jan; 19(1):215-222. PubMed ID: 27739008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease.
    Drobne D; Kurent T; Golob S; Švegl P; Rajar P; Hanžel J; Koželj M; Novak G; Smrekar N; Ferkolj I; Štabuc B
    Aliment Pharmacol Ther; 2019 Apr; 49(7):880-889. PubMed ID: 30784100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience.
    Mitchell RA; Shuster C; Shahidi N; Galorport C; DeMarco ML; Rosenfeld G; Enns RA; Bressler B
    Can J Gastroenterol Hepatol; 2016; 2016():5203898. PubMed ID: 27957480
    [No Abstract]   [Full Text] [Related]  

  • 17. A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease.
    Piester T; Frymoyer A; Christofferson M; Yu H; Bass D; Park KT
    Inflamm Bowel Dis; 2018 Jan; 24(2):227-234. PubMed ID: 29361094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
    Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
    Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Infliximab Trough Levels and the Occurrence of Paradoxical Manifestations in Patients with Inflammatory Bowel Disease: a Case-Control Study.
    Coutzac C; Chapuis J; Poullenot F; Chabrun E; Capdepont M; Blanco P; Laharie D
    J Crohns Colitis; 2015 Nov; 9(11):982-7. PubMed ID: 26351388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease.
    Lee JM; Kim YJ; Lee KM; Yoon H; Lee BI; Kim DB; Kang D
    Scand J Gastroenterol; 2018; 53(10-11):1280-1285. PubMed ID: 30351977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.